- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- fluorouracil, leucovorin calcium, topotecan hydrochloride
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 697–720
of 3,664
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma
- Interventions
- bb21217
- Biological
- Lead sponsor
- 2seventy bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 11
- States / cities
- San Francisco, California • Tampa, Florida • Atlanta, Georgia + 6 more
- Conditions
- Multiple Myeloma
- Interventions
- JCARH125, JCARH125 + anakinra
- Biological
- Lead sponsor
- Juno Therapeutics, a Subsidiary of Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 16 more
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition
- Interventions
- filgrastim, cyclosporine, methylprednisolone, prednisone, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 10 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Multiple Myeloma
- Interventions
- Belantamab mafodotin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 6
- States / cities
- San Francisco, California • Atlanta, Georgia • Westwood, Kansas + 3 more
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Fibrillary Astrocytomas, Oligodendroglioma, Diffuse Intrinsic Brainstem Glioma, Diffuse Intrinsic Pontine Glioma, DIPG Brain Tumor, H3 K27M
- Interventions
- SIACI of cetuximab and bevacizumab
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Bladder Cancer
- Interventions
- B-701, Pembrolizumab
- Drug
- Lead sponsor
- Mark Pomerantz, MD
- Other
- Eligibility
- 18 Years to 18 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cancer
- Interventions
- fatigue assessment and management, management of therapy complications, psychosocial assessment and care
- Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 9
- States / cities
- Stanford, California • Denver, Colorado • Gainesville, Florida + 5 more
- Conditions
- Leukemia
- Interventions
- filgrastim, cladribine, cytarabine, imatinib mesylate
- Biological · Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis
- Interventions
- Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Gainesville, Florida • Rochester, Minnesota + 3 more
- Conditions
- Lymphoma, B-Cell, Lymphoma, T-Cell
- Interventions
- STP938
- Drug
- Lead sponsor
- Step Pharma, SAS
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Sarasota, Florida • New York, New York
- Conditions
- Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Infliximab, Positron Emission Tomography, Talquetamab, Teclistamab, X-Ray Imaging
- Procedure · Biological · Drug
- Lead sponsor
- Naresh Bumma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Carfilzomib, Isatuximab, Pomalidomide
- Drug · Biological
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- Carfilzomib, Dexamethasone, Pomalidomide
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Denver, Colorado • New Haven, Connecticut + 8 more
- Conditions
- Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Castrate Resistant Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Head-and-neck Squamous Cell Carcinoma, Endometrial Cancer, Ovarian Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Urothelial Carcinoma
- Interventions
- DR-0202
- Drug
- Lead sponsor
- Dren Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 10
- States / cities
- Denver, Colorado • Orlando, Florida • Sarasota, Florida + 7 more
- Conditions
- Multiple Myeloma
- Interventions
- Clofarabine
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Solid Tumors
- Interventions
- RMC-5552
- Drug
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 8
- States / cities
- Irvine, California • Sacramento, California • San Francisco, California + 5 more
- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib, Venetoclax, Dexamethasone
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Hollywood, Florida + 15 more
- Conditions
- Recurrent Cutaneous Melanoma, Recurrent Lip and Oral Cavity Carcinoma, Recurrent Malignant Endocrine Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Male Reproductive System Neoplasm, Recurrent Malignant Mesothelioma, Recurrent Malignant Neoplasm of Multiple Primary Sites, Recurrent Malignant Oral Neoplasm, Recurrent Malignant Pharyngeal Neoplasm, Recurrent Malignant Skin Neoplasm, Recurrent Malignant Soft Tissue Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Thyroid Gland Neoplasm, Recurrent Malignant Urinary System Neoplasm, Refractory Cutaneous Melanoma, Refractory Malignant Bone Neoplasm, Refractory Malignant Endocrine Neoplasm, Refractory Malignant Female Reproductive System Neoplasm, Refractory Malignant Male Reproductive System Neoplasm, Refractory Malignant Mesothelioma, Refractory Malignant Neoplasm of Multiple Primary Sites, Refractory Malignant Oral Neoplasm, Refractory Malignant Pharyngeal Neoplasm, Refractory Malignant Skin Neoplasm, Refractory Malignant Soft Tissue Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Malignant Thyroid Gland Neoplasm, Refractory Malignant Urinary System Neoplasm
- Interventions
- Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Cyclophosphamide, Etoposide
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Months to 40 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hodgkin Lymphoma
- Interventions
- Idelalisib
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 3
- States / cities
- New York, New York • Houston, Texas • Seattle, Washington
- Conditions
- Diffuse Large-cell B-cell Lymphoma
- Interventions
- Plamotamab, Tafasitamab, Lenalidomide
- Biological · Drug
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Warm Antibody Autoimmune Hemolytic Anemia
- Interventions
- Acalabrutinib
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Carmustine, Etoposide, Cytarabine, Melphalan, Pegfilgrastim, 19-28z T CELLS, Autologous Stem Cell Transplantation
- Drug · Biological · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Leukemia, Lymphocytic, Lymphoma
- Interventions
- BCX-1777
- Drug
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Eligibility
- 0 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- Houston, Texas